

**This Page Is Inserted by IFW Operations  
and is not a part of the Official Record**

## **BEST AVAILABLE IMAGES**

**Defective images within this document are accurate representations of the original documents submitted by the applicant.**

**Defects in the images may include (but are not limited to):**

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIGURE 1

1 2 3 4 5 6 7 8



$\beta$ -actin

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIGURE 2


1 2 3 4 5




IL-10

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

# FIGURE 3



**FIGURE 4**



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIGURE 5A

1 2 3 4 5




FIGURE 5B

1 2 3 4 5



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

**FIGURE 6**



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

## FIGURE 7

	<b>Leader -----</b>	
RAT	ATGGGCAGTCCGGTATTGAGGAGACCTTTCTGCCATCTGTCCACCTACAGCCTGCTCTGGGCCATAG	67
MOU	-----T-----C-----A-T---G-----	67
HUM	--GA-----TG---C---CT-----T-----G-T---T---G-	55
	V-like domain -----	
RAT	CAGCAGTAGCGCTGAGCACAGCTCAAGTGGGAAGTGGTGACCCAGGATGAAAGAAAGCTGCTGCACAC	134
MOU	-----GC-----	134
HUM	-----G-T---T-----A-----C-----A---T---	122
RAT	AACTGCATCCTTACGCTGTTCTCTAAAAACAACCCAGGAACCCTTGATTGTGACATGGCAGAAAAAG	201
MOU	-----A-----T-----	201
HUM	-----T-----AAA-C-----GC-----ATG-----G---C-C-----	189
RAT	AAAGCCGTAGGCCCAGAAAAATGGTCACTTACAGCAAAGCCCATGGGGTTGTCTTCAGCCCACCT	268
MOU	-----GA-----C-----A-----A-C---TG---	268
HUM	-----T---A-----C-T---G-GAA-----G---G---C---TG---	256
RAT	ACAAAGACAGGATAAACATCACTGAGCTGGGACTCTTGAACACAAGCATCACCTTCTGGAACACAAC	335
MOU	-----TG---A-----G---T-----CA	335
HUM	-T---G---A-----T---CC-----C-A---T---C-----T-TC--	323
RAT	CCTGGATGATGAGGGTTGCTACATGTGTCTCTTCAACATGTTTGGATCTGGGAAGGTCTCTGGGACA	402
MOU	-A-T-GA---GA---C-----C-----T---CA-----A-A---	402
HUM	-----G---A---G---T-----T-CC---T-T-----A-A---G	390
	C-like domain -----	
RAT	GCTTGCCTTACTCTCTATGTACAGCCCATAGTACACCTTCACTACAACCTATTTTGAAGACCACCTAA	469
MOU	-----C-----	469
HUM	--C-----C---CG-----TC-----A-TC-C-----	457
RAT	ACATCACGTGCTCTGCAACTGCCCGCCCAGCCCCTGCCATCTCCTGGAAGGGCACTGGGTGAGGAAT	536
MOU	-----T-----G-----T-----A-----T-----A-----	536
HUM	-T-----T-----C-----CATGG---T-----T-C-C-----	524
RAT	TGAGAATAGTACTGAGAGTCACTCCCATTCAAATGGGACTACATCTGTCAACAGCATCCTCCGGGTC	603
MOU	-----C-----T-----	603
HUM	---A-----A-T---C---TG---T---CC-----C---G-----T-----ATA--	591
RAT	AAAGACCCCAAACTCAGGTTGGAAAGGAAGTGATCTGCCAGGTTTTTATACTTGGGGAATGTGATTG	670
MOU	-----	670
HUM	-----T---G-A-----G---G-----GC-GC---C-----C---CC-	658
	Transmembrane region -----	
RAT	ACTACAAGCAGAGTCTGGACAAAGGATTTTGGTTTTTCAGTCCCACTGCTGCTGAGCATTGTTTCTCT	737
MOU	-----T-----T---A-----	737
HUM	---TT-----A-CCG-CA-----C-A-----T---G---AT---A-----C---	725
	Cytoplasmic region -----	
RAT	GGTAATTCTTCTGGTCTTGATCTCCATCTTATTATACTGGAAACGGCACCGAAATCAGGAGCGGGGT	804
MOU	-----A-----C-----T-----	804
HUM	-----C---C-A---A---C-G-----T---G-----C---A---	792
RAT	GAGTCATCACAGGGGATGCAAAGAATGAAATAA	837
MOU	---A-----	837
HUM	---TG-----AG-T---A---C---	825



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

## FIGURE 8

```

      Leader sequence-----
-30                                     -1
RAT  M G S P V F R R P F C H L S T Y S L L W A I A A V A L S T A
MOU  -----L-----I-----G-----
HUM      - I - M - - - S - - - - V - - V M - - - - V - - C - -

      |V-like domain (domain I) -----
RAT  Q V E V V T Q D E R K L L H T T A S L R C S L K T T Q E P L
MOU  -----A-----S-----
HUM  ---Q-----E---Y-----K-----QNA---A---

      31                               **
RAT  I V T W Q K K K A V G P E N M V T Y S K A H G V V I Q P T Y
MOU  -----S-----T-----A---
HUM  -----E N-----

      61                               **
RAT  K D R I N I T E L G L L N T S I T F W N T T L D D G G C Y M
MOU  -----V-----W--S-----H I G-----
HUM  ---K---Q---Q---T---I---E---

      91*                               **
      |C-like domain (domain II) -----
RAT  C L F N M F G S G K V S G T A C L T L Y V Q P I V H L H Y N
MOU  -----T-----Q-----
HUM  -----F G--I-----V-----S-----K

      121                               **
RAT  Y F E H H L N I T C S A T A R P A P A I S W K G T G S G I E
MOU  -----T-----T-----
HUM  F S-----M V F-----V P R-----

      151**
RAT  N S T E S H S H S N G T T S V T S I L R V K D P K T Q V G K
MOU  -----F-----
HUM  -----V T L S--P-----H I-----N-----

      181                               *
      |Transmembrane region -----
RAT  E V I C Q V L Y L G N V I D Y K Q S L D K G F W F S V P L L
MOU  -----
HUM  -----H---T--T--F---T V N---Y-----


      211                               |Cytoplasmic region -----
RAT  L S I V S L V I L L V L I S I L L Y W K R H R N Q E R G E S
MOU  -----I-----
HUM  -----V-----D-----L

      241
RAT  S Q G M Q R M K
MOU  -----
HUM  -----V--K---T


```

\* invariant cysteine residues; \*\* invariant asparagine (N-linked oligosaccharides)

**FIGURE 9A**




**FIGURE 9B**




**CELLS added to C57BL/6 RESPONDER SPLEEN CELLS**

**FIGURE 10**



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		


**FIGURE 11**




**NPC from Flt3 treated mice**

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

## FIGURE 12




**FIGURE 13**



CELLS added to C3H RESPONDER SPLEEN CELLS


**FIGURE 14**




NPC cells infused into renal transplant recipients



**FIGURE 15**




**FIGURE 16**




**Monoclonal antibodies added to culture**

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

**FIGURE 17A**



**FIGURE 17B**



Monoclonal antibodies added to culture

- IL-2 (pg/ml)
- IFN- $\gamma$  (ng/ml)
- ▨ IL-4 (pg/ml)
- ▩ IL-10 (ng/ml)

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIGURE 18A






FIGURE 18B




# **FIGURE 19A**



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

**FIGURE 19B**








FIGURE 20




# **FIGURE 21A**



# **FIGURE 21B**




# **FIGURE 22A**



- BL/6 with BL/6
- BL/6 with C3H:IgG
- BL/6 with C3H:CD200Fc
- ▲- Normal C3H+IgG
- △- Normal C3H:CD200Fc

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

**FIGURE 22B**



CD200Fc reverses protection from early mortality in C57BL/6 mice immunized with CD80-transfected EL4 cells






FIGURE 23

**FIGURE 24A**




APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

**FIGURE 24B**



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

Relative CD200 mRNA expression in spleen following immunization with EL4-CD86 vs EL4-CD80




Cells used for immunization of C57BL/6


FIGURE 25



**FIGURE 26A**




**FIGURE 26B**






**FIGURE 27B**




APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		


## FIGURE 29A




## FIGURE 29B




## FIGURE 30A



## FIGURE 30B



# **FIGURE 31A**



# **FIGURE 31B**

